Stanford Medicine researchers reported this week that an intranasal vaccine formula protected mice against a striking range of respiratory threats, from SARS-CoV-2 to bacterial infections, in what they describe as a major step toward a single shot that guards against many pathogens at once. The announcement lands alongside a broader push by the National Institutes of Health to test universal influenza vaccine candidates in human trials, and a new World Health Organization assessment that next-generation flu vaccines alone could save millions of lives. Taken together, these developments signal that the long-elusive goal of a universal respiratory vaccine is closer to clinical reality than at any point in modern medicine.
A Nasal Spray That Fights Viruses and Bacteria Alike
The Stanford team’s approach breaks from conventional vaccine design in a fundamental way. Rather than training the immune system to recognize one specific virus, the intranasal liposomal formulation uses a combination of TLR4 and TLR7/8 ligands alongside a model antigen to activate broad mucosal defenses in the nose and lungs. In peer-reviewed results published in Science, the formula protected mice against multiple respiratory pathogens, including SARS-CoV-2, other coronaviruses, Staphylococcus aureus, and Acinetobacter. That breadth is unusual: most vaccine candidates target a single virus family, not bacteria and viruses simultaneously, and the findings suggest that tuning innate immune pathways at the site of infection could offer cross-cutting protection without needing a bespoke vaccine for every new threat.
The practical implication is significant for anyone who has watched seasonal respiratory illness seasons stack viral and bacterial co-infections on top of each other. If the same immune-priming strategy works in humans, a single nasal spray could reduce the need for separate flu, COVID, and pneumonia vaccines and might blunt secondary bacterial pneumonias that often follow viral infections. Stanford Medicine researchers have described the results as an astonishing step forward in the quest for a universal vaccine, but they also stress that these are early-stage animal data. If the initial protection signals hold up, larger studies would follow, starting with safety evaluations and dose-finding in healthy volunteers before any move toward controlled human exposure to infections.
NIH Nanoparticle Trials Target Universal Flu Protection
While Stanford’s work aims across the respiratory threat spectrum, the NIH has been running a parallel, more focused campaign against influenza specifically. The agency launched a first-in-human Phase 1 trial of FluMos-v1, a mosaic quadrivalent influenza nanoparticle vaccine, at the NIH Clinical Center to gather early safety and immune-response data. According to an NIH announcement, the candidate is designed to spur antibodies against multiple influenza A and B strains at once, with the long-term ambition of producing longer-lasting and broader flu protection that would not require annual reformulation. Preclinical characterization of FluMos-v1, reported in Scientific Reports, detailed the nanoparticle’s composition, assembly, size, hemagglutinin distribution, and antibody binding ratios, confirming that the mosaic structure displays antigens from several flu strains on a single particle in a highly ordered array.
The NIH program is not resting on one candidate. A separate trial registration for FluMos-v2, a mosaic hexavalent influenza vaccine, shows the agency is already iterating toward broader antigen coverage and comparing adjuvant strategies to fine-tune immune responses. Meanwhile, the NIH Vaccine Research Center has tested other universal flu approaches: the H1ssF ferritin nanoparticle vaccine completed a Phase 1 trial with results summarized by NIAID researchers, and a separate Phase 1 dose-escalation trial of H10ssF, a group-2 influenza HA-stem ferritin nanoparticle, was published in npj Vaccines. These multiple parallel tracks reflect a deliberate strategy in which different nanoparticle architectures attack distinct parts of the influenza virus, and NIH scientists are betting that at least one will produce durable, cross-strain immunity in humans that can withstand both seasonal drift and the emergence of new pandemic-capable strains.
Why Annual Flu Shots Keep Falling Short
The urgency behind these universal vaccine programs becomes clear when set against the limitations of current seasonal shots. Each year, global health authorities review surveillance data and recommend which influenza A and B lineages manufacturers should build into the coming season’s vaccines, a process that for the United States leads to FDA strain-selection decisions months before flu season begins. For the 2025-2026 U.S. season, regulators again settled on a trivalent formulation with two influenza A subtype viruses, H1N1 and H3N2, plus one influenza B virus, reflecting what they expect to circulate most widely. The long lead time needed to grow vaccine viruses in eggs or cell culture means that if the virus drifts genetically after those decisions, the resulting shots may be a poor match, and effectiveness can drop sharply even when vaccination rates are high.
That annual guessing game is exactly what universal vaccine researchers are trying to eliminate. By targeting conserved structures on the virus, such as the hemagglutinin stem region used in the H1ssF and H10ssF candidates, or by displaying antigens from many strains on a single mosaic nanoparticle like FluMos-v1, the goal is a vaccine that remains effective across multiple flu seasons and against strains that have not yet emerged. For ordinary people, the payoff would be straightforward: fewer injections, fewer mismatched seasons, and a standing defense against the kind of novel flu strain that could trigger the next pandemic-scale event. Public health educators emphasize that even current flu shots reduce the risk of severe illness and hospitalization, and resources such as MedlinePlus offer accessible explanations of influenza, vaccines, and who benefits most from annual protection while the field works toward more universal options.
From Lab Bench to Public Health Tool
Turning experimental platforms into practical tools will require more than promising mouse data and early human trials. Regulators will demand clear evidence that broad-acting vaccines do not trigger excessive inflammation or autoimmunity, especially for intranasal formulations that stimulate mucosal tissues directly. Manufacturing will also be a hurdle: complex nanoparticles and liposomal mixtures must be produced at scale with tight quality control, and companies will need to demonstrate that these products remain stable during storage and transport. To prepare communities for these advances, NIH-supported initiatives such as the Science Education partnership are working to improve public understanding of how vaccines are developed and tested, aiming to build trust before new technologies reach pharmacies and clinics.
Communication will be just as critical as clinical data. The COVID-19 pandemic exposed how misinformation can undermine even highly effective vaccines, and health agencies are adapting their outreach accordingly. The NIH’s consumer-friendly publication News in Health has increasingly highlighted stories that explain vaccine research in plain language, from how nanoparticle platforms work to why universal vaccines might change the rhythm of seasonal illness. If intranasal broad-spectrum sprays and universal flu shots succeed in late-stage trials, they could eventually be woven into routine immunization schedules for children, older adults, and people with chronic conditions. Until then, researchers caution that incremental progress (better strain coverage, longer-lasting antibodies, and more convenient delivery methods) will be the stepping stones that move universal respiratory vaccines from aspiration to everyday reality.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
